Lisata Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| LSTA | PCSA | CTXR | TPST | MNOV | CNSP | |
|---|---|---|---|---|---|---|
| Market cap | 11.45M | 5.41M | 15.13M | 9.26M | 71.37M | 6.34M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.9 | -0.5 | -0.4 | -0.4 | -2.8 | -11.1 |
| Price/book | 1.2 | -17.0 | 0.2 | -6.8 | 1.9 | 0.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −54.89% | −75.51% | −58.18% | −95.15% | +3.57% | −33.30% |
| Today | −2.75% | −0.26% | −3.87% | −1.13% | +2.11% | −4.62% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All LSTA news ›Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
Soluna Agrees to Form Strategic Partnership with Applied Digital to Develop Wind-Powered AI Data Center in Texas INVE Technologies Announces the Commencement of a $20 Million Modified Dutch Auction Tender Offer for its Common Stock SCHMID…
Small cap wrap: Nextech3D.ai, Nine Mile Metals, Lisata Therapeutics, Dune Oil...
Standard Uranium Ltd (TSX-V:STND, OTCQB:STTDF, FRA:9SU0) said its C$3 million private placement with a Southeast Asian strategic investor is progressing as planned, and the TSX Venture Exchange has granted more time to complete it. The…
Lisata Therapeutics wins new US patent for pancreatic cancer drug
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has been granted a new US patent covering its experimental drug certepetide for the treatment of pancreatic cancer and other solid tumors, the company said. The US Patent and Trademark Office…
Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.…
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
Earlier Phase 1 findings suggest MAR002 may allow less frequent dosing than the daily injections required by the current standard of care. Phase 1 results presented in June 2026 showed sustained IGF-1 suppression. Marea said the drug's…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- proactiveinvestors.com2
- stocktitan.net2
- biospace.com1
- globenewswire.com1
- manilatimes.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.